Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival

An investigator-driven, retrospective study to compare long-term survival-data (10-year follow-up) of patients with coronary artery disease (CAD), previously enrolled in the SYNTAX trial, who were randomized to percutaneous coronary intervention (PCI) using a paclitaxel (TAXUS) drug-eluting-stent (DES) or coronary artery bypass grafting (CABG).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

21 year–100 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients which have previously been enrolled in the SYNTAX trial (randomized and registry patients)

Treatment and study plan

No intervention will take place for this retrospective and observational study.

Other

No intervention will take place for this retrospective and observational study.

Primary outcomes

Long-term survival status

Time frame: 10-year

All-cause death

Secondary outcomes

Cause of death

Time frame: 10-year

Cause-specific death, separated in cardiovascular and non-cardiovascular death with specific causes for cardiovascular deaths.

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Acronym: SYNTAXES

Important dates

Study start: 2016
Primary completion: 2019
Study completion: 2019
First posted: Jan 31, 2018
Registry last updated: Jan 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed